Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for medical industry professionals · Tuesday, October 16, 2018 · 465,244,428 Articles · 3+ Million Readers

Fragile X Syndrome Key Players - Anavex Life Sciences Corp, DRI Biosciences Corp Market Analysis & Forecast 2017 to 2022

PUNE, INDIA, April 6, 2018 / -- with their unique quality of simplifying the market research study, presents a deep diving study report “Fragile X Syndrome - Pipeline Review, H1 2018”

Fragile X Syndrome 


Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Fragile X syndrome is caused by a change in a gene called FMR1. Fragile X syndrome occurs both in male and female. Symptoms include delay in crawling, walking, or twisting, hyperactive or impulsive behavior, speech and language delay and intellectual disability.

Click here for sample report @


Major Key Players

Anavex Life Sciences Corp

Confluence Pharmaceuticals LLC

DRI Biosciences Corp

Eli Lilly and Co

Epigen Biosciences Inc

Fulcrum Therapeutics ...

Fragile X Syndrome Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Fragile X Syndrome   - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Fragile X Syndrome  , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 5, 13 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Fragile X Syndrome pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Fragile X Syndrome - Competitive Analysis

Key players are making innovative developments in Fragile X Syndrome industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector


The pipeline guide provides a snapshot of the global therapeutic landscape of Fragile X Syndrome.

The pipeline guide reviews pipeline therapeutics for Fragile X Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Fragile X Syndrome therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Fragile X Syndrome therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for Fragile X Syndrome.


For Detailed Reading Please visit @

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here

Powered by EIN Presswire